Subtype
Lung Small Cell Carcinoma
CI-CAN-00005832SCLCExplore in graph →
381 active trials6 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005832SCLCExplore in graph →
Clinical trials
1,100 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (157)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04560972 | LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer | active not recruiting | Phase 1 | 3 | City of Hope Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07424547 | Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 386 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT03923270 | Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | active not recruiting | Phase 1 | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors(BetaBart) | recruiting | Phase 1 / Phase 2 | 61 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07480213 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)(DART-NK-SCLC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04802174 | Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers | active not recruiting | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07472647 | SYS6090 Combination Therapy in Advanced Lung Cancer | not yet recruiting | Phase 1 / Phase 2 | 596 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Mar 16, 2026 | clinicaltrials |
| NCT06681220 | Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC(Relapsed SCLC) | recruiting | Phase 1 / Phase 2 | 166 | VA Office of Research and DevelopmentFED | 1 | Mar 11, 2026 | clinicaltrials |
| NCT02402920 | Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer | completed | Phase 1 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07391813 | SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer(SNB-101-101) | recruiting | Phase 1 / Phase 2 | 55 | SN BioScienceINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04170946 | Talazoparib and Thoracic RT for ES-SCLC(Talazoparib) | recruiting | Phase 1 | 24 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03223155 | Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer(COSINR) | active not recruiting | Phase 1 | 78 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 174 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04471727 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | active not recruiting | Phase 1 / Phase 2 | 232 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Tasca TherapeuticsINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07413042 | A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment | recruiting | Phase 1 | 24 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07414927 | A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy | not yet recruiting | Phase 1 / Phase 2 | 48 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03830918 | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy | active not recruiting | Phase 1 / Phase 2 | 59 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07107490 | A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER | recruiting | Phase 1 | 122 | Chugai PharmaceuticalINDUSTRY | 3 | Feb 6, 2026 | clinicaltrials |
| NCT04640480 | Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors | completed | Phase 1 | 21 | SN BioScienceINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT03467360 | Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma(ICAR) | recruiting | Phase 1 | 27 | Centre Antoine LacassagneOTHER | 2 | Jan 20, 2026 | clinicaltrials |
| NCT03575793 | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 39 | Salma SabbourOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT05978284 | Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | recruiting | Phase 1 / Phase 2 | 54 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07038096 | ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | recruiting | Phase 1 / Phase 2 | 350 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03319940 | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) | active not recruiting | Phase 1 | 269 | AmgenINDUSTRY | 13 | Nov 19, 2025 | clinicaltrials |
| NCT06283719 | Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 265 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05244239 | Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer | recruiting | Phase 1 | 22 | Emory UniversityOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT03392064 | A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC | suspended | Phase 1 | 6 | AmgenINDUSTRY | 1 | Oct 15, 2025 | clinicaltrials |
| NCT05329623 | A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. | completed | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 10, 2025 | clinicaltrials |
| NCT04631029 | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | completed | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07206563 | Penfluridol for Relapsed/Refractory Small Cell Cancers | not yet recruiting | Phase 1 / Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT04885998 | AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) | completed | Phase 1 | 23 | AmgenINDUSTRY | 6 | Sep 29, 2025 | clinicaltrials |
| NCT02514447 | Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | completed | Phase 1 / Phase 2 | 123 | G1 Therapeutics, Inc.INDUSTRY | 8 | Sep 25, 2025 | clinicaltrials |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 23 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06505824 | A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT01737502 | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 29 | Mayo ClinicOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06016270 | A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 10 | STCube, Inc.INDUSTRY | 2 | Sep 5, 2025 | clinicaltrials |
| NCT07141771 | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | not yet recruiting | Phase 1 / Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 6 | Aug 20, 2025 | clinicaltrials |
| NCT07132957 | A Study of AL8326 in Healthy Subjects | completed | Phase 1 | 6 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT07110363 | A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer | not yet recruiting | Phase 1 | 58 | Biotroy TherapeuticsINDUSTRY | 0 | Aug 7, 2025 | clinicaltrials |
| NCT06592638 | A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer | recruiting | Phase 1 | 30 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Apr 7, 2026source: clinicaltrials